CeraPedics LLC
This article was originally published in Start Up
Executive Summary
It's truism in spine that 4% of patients rack up 75% in costs, and expensive BMP products, which are highly successful at enhancing fusion rates, are the "high octane" products for more difficult cases-high-risk patients or the obese, for example. The market needs a product for the majority of cases, believes the founder of CeraPedics LLC, and he believes his company has it in its P-15, a growth factor that's a small peptide.